Jan. 29, 2014, 8:29 AM
- Fluidigm (FLDM) agrees to acquire DVS Sciences for $207.5M in cash and stock in a deal it says will enable it to offer a comprehensive portfolio of advanced technologies serving the growing single-cell genomics and proteomics markets.
- FLDM says DVS is best known for its multi-parameter single-cell protein analysis systems, including the the CyTOF2 Mass Cytometer, which analyzes antibody/metal complexes using atomic mass spectrometry.
Fluidigm Corp. develops, manufactures, and markets microfluidic systems for growth markets such as single-cell genomics, applied genotyping and sample preparation for targeted resequencing, in the life science and agricultural biotechnology, or Ag-Bio, industries. Its proprietary microfluidic... More
Industry: Scientific & Technical Instruments
Country: United States